Regulus Therapeutics has appointed Douglas Williams to its board of directors.
Williams is currently executive vice president of research and development at Biogen Idec, a Regulus collaborator that recently purchased a $5 million convertible note from the firm.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
